Company Overview

At Filamon, we are pioneering a bold, science-driven approach to address chronic inflammatory and degenerative diseases – conditions that continue to impact millions worldwide, especially as we age.

Our focus is on providing the ageing population with a renewed chance for more productive and independent living. Through groundbreaking research and technology, we are reshaping what it means to treat age-related chronic diseases.

The challenge with conventional treatments is that they are monomodal, designed to act on a single pathway or gene. However, chronic inflammation is far more complex, involving an intricate web of signals and gene interactions. Our breakthrough solution lies in four multimodal technology platforms capable of influencing hundreds of genes simultaneously. This innovation enables Filamon to design drugs that address chronic inflammation at its root, offering new hope for patients with conditions once considered intractable.

Our research approach treats chronic inflammatory and degenerative diseases not as isolated conditions but as interconnected outcomes of widespread inflammation in the body.

From heart disease and arthritis to cancer and dementia, we believe these diseases stem from the same underlying processes. By targeting inflammation at the core, Filamon’s therapies are designed to address multiple conditions, providing powerful treatment options for the ageing population, many of whom experience multiple chronic diseases.

Filamon’s innovative technologies enable us to tackle even the most aggressive diseases. In oncology, our clinical-stage inhibitor kesonotide targets the inflammatory processes fueling cancer growth and spread. Meanwhile, LYTAP-001 is designed to revolutionise EGFR inhibition by addressing the limitations of current treatments, aiming for durable outcomes in patients with hard-to-treat cancers. These assets underscore our dedication to advancing treatment options for complex diseases.